Highlights
- Retatrutide, a triple receptor agonist targeting GIP, GLP-1, and glucagon receptors, provides significant analgesic benefits in adults with knee osteoarthritis and obesity.
- Phase 3 TRIUMPH-4 and TRIUMPH-1-OA trials demonstrate robust reductions in WOMAC pain scores and body weight up to 80 weeks with once-weekly subcutaneous retatrutide.
- Weight loss achieved surpasses 20% on average, which likely contributes synergistically to pain relief and functional improvement.
- Gastrointestinal adverse events were common, and serious adverse events were more frequent with retatrutide than placebo, emphasizing the need for careful safety monitoring.
Background
Specialty calculators
For clinical reference; use professional judgment.
